Extracorporeal membrane oxygenation without systemic anticoagulation: a case-series in challenging conditions.
Extracorporeal membrane oxygenation (ECMO)
anticoagulation
bleeding
hemorrhage
hemostasis
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
ppublish
Résumé
Extracorporeal membrane oxygenation (ECMO) use in patients with active bleedings or traumatic injuries may be challenging because of the risk of refractory haemorrhage related to systemic anticoagulation (SA). Technological advancements, especially heparin coated circuits, allowed ECMO application with a mild or no anticoagulation regimen in some circumstances. We herein report a limited case-series of ECMO application without anticoagulation. ECMO without SA was established in 6 patients. Four of them received veno-arterial mode. Full heparin antagonization with protamine was provided in 3 post-cardiotomy cases. Tip-to-tip heparin-coated ECMO circuit was used in 4 patients, whereas heparin-coated tubing and no heparin-coated cannulas were applied for the remaining subjects. Mean duration of support and pump flow were 10±4 hours and 3.0±0.7 litres respectively. No ECMO related complication or oxygenator failure occurred, nor was clotting of the circuit observed at inspection. All patients were weaned from ECMO and half of them survived and were discharged. Short ECMO duration without anticoagulation was feasible and provided effective cardiopulmonary support in patients with active bleeding or high hemorrhagic risk. Further investigations are needed to evaluate its benefits or limitations for a protracted time, in a wider range of clinical conditions and in larger patient populations.
Sections du résumé
BACKGROUND
BACKGROUND
Extracorporeal membrane oxygenation (ECMO) use in patients with active bleedings or traumatic injuries may be challenging because of the risk of refractory haemorrhage related to systemic anticoagulation (SA). Technological advancements, especially heparin coated circuits, allowed ECMO application with a mild or no anticoagulation regimen in some circumstances. We herein report a limited case-series of ECMO application without anticoagulation.
METHODS
METHODS
ECMO without SA was established in 6 patients. Four of them received veno-arterial mode. Full heparin antagonization with protamine was provided in 3 post-cardiotomy cases. Tip-to-tip heparin-coated ECMO circuit was used in 4 patients, whereas heparin-coated tubing and no heparin-coated cannulas were applied for the remaining subjects.
RESULTS
RESULTS
Mean duration of support and pump flow were 10±4 hours and 3.0±0.7 litres respectively. No ECMO related complication or oxygenator failure occurred, nor was clotting of the circuit observed at inspection. All patients were weaned from ECMO and half of them survived and were discharged.
CONCLUSIONS
CONCLUSIONS
Short ECMO duration without anticoagulation was feasible and provided effective cardiopulmonary support in patients with active bleeding or high hemorrhagic risk. Further investigations are needed to evaluate its benefits or limitations for a protracted time, in a wider range of clinical conditions and in larger patient populations.
Identifiants
pubmed: 32642115
doi: 10.21037/jtd.2020.04.54
pii: jtd-12-05-2113
pmc: PMC7330289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2113-2119Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.04.54). RL reports other from Medtronic, other from LivaNova, other from EUROSETS, outside the submitted work. MK serves as an unpaid editorial board member of Journal of Thoracic Disease from Sep 2018 to Aug 2020. The other authors have no conflicts of interest to declare.
Références
J Cardiothorac Vasc Anesth. 2019 May;33(5):1216-1220
pubmed: 30181084
Anesth Analg. 2011 Dec;113(6):1319-33
pubmed: 22003219
World J Emerg Surg. 2015 Mar 12;10:15
pubmed: 25774211
J Trauma Acute Care Surg. 2012 May;72(5):1444-7
pubmed: 22673280
Perfusion. 1999 Nov;14(6):489-93
pubmed: 10585157
Crit Care. 2013 Apr 18;17(2):R73
pubmed: 23594433
Ann Am Thorac Soc. 2016 Dec;13(12):2242-2250
pubmed: 27690525
Innovations (Phila). 2010 Nov;5(6):424-9
pubmed: 22437638
Transfus Med Rev. 2015 Apr;29(2):90-101
pubmed: 25595476
J Thorac Cardiovasc Surg. 2018 Feb;155(2):643-649
pubmed: 29033041
Crit Care. 2011;15(6):R275
pubmed: 22099212
Clin Exp Emerg Med. 2018 Sep;5(3):204-207
pubmed: 29706054
Eur J Cardiothorac Surg. 2011 Dec;40(6):1396-405; discussion 1405
pubmed: 21507672
Semin Cardiothorac Vasc Anesth. 2009 Sep;13(3):154-75
pubmed: 19767408
Curr Opin Crit Care. 2018 Aug;24(4):286-291
pubmed: 29901460
J Thromb Haemost. 2015 Jun;13 Suppl 1:S336-42
pubmed: 26149045
Int J Artif Organs. 2006 Dec;29(12):1121-31
pubmed: 17219352
Resuscitation. 2010 Jul;81(7):804-9
pubmed: 20378236
Perfusion. 2015 Jul;30(5):403-6
pubmed: 25300436
J Cardiothorac Vasc Anesth. 2017 Jun;31(3):869-875
pubmed: 28082026
Multidiscip Respir Med. 2013 Feb 27;8(1):16
pubmed: 23442499
Biomater Sci. 2016 Aug 19;4(8):1161-83
pubmed: 27226170
Semin Thromb Hemost. 2018 Feb;44(1):20-29
pubmed: 28898902
Aust N Z J Surg. 1995 May;65(5):331-3
pubmed: 7741676
Crit Care Med. 2015 Dec;43(12):e581-4
pubmed: 26308437
Gen Thorac Cardiovasc Surg. 2019 Nov;67(11):982-986
pubmed: 30120673
J Thorac Dis. 2017 Dec;9(12):5017-5029
pubmed: 29312706
J Crit Care. 2014 Jun;29(3):473.e1-5
pubmed: 24508200